ANAVEX2-73 oral liquid + Placebo oral liquid

Phase 2/3Completed
0 watching 0 views this week Active
57
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome

Trial Timeline

Jul 1, 2020 → Jun 30, 2023

About ANAVEX2-73 oral liquid + Placebo oral liquid

ANAVEX2-73 oral liquid + Placebo oral liquid is a phase 2/3 stage product being developed by Anavex Life Sciences for Rett Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04304482. Target conditions include Rett Syndrome.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT04304482Phase 2/3Completed

Competing Products

20 competing products in Rett Syndrome

See all competitors
ProductCompanyStageHype Score
Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
85
Esomeprazole + LansoprazoleAstraZenecaApproved
85
Esomeprazole MagnesiumAstraZenecaApproved
85
AZD5213 and placeboAstraZenecaPhase 2
52
fingolimod (FTY720)NovartisPhase 1/2
41
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
AripiprazoleBristol Myers SquibbPre-clinical
22
NBI-98854Neurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 1
30
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Abobotulinum toxin AIpsenPre-clinical
20
GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
74
GWP42003-PJazz PharmaceuticalsPhase 3
74
trofinetideAcadia PharmaceuticalsPhase 3
72
TrofinetideAcadia PharmaceuticalsPhase 3
72